In AMPLIFY, in patients receiving treatment for DVT and PE, ELIQUIS demonstrated comparable efficacy and a significant reduction in the risk of major bleeding compared with enoxaparin / warfarin.1*
Discover the data supporting ELIQUIS in DVT / PE
Adapted from Agnelli et al. 2013.1
Please click here to access the ELIQUIS Patient Information Leaflet.
* The AMPLIFY clinical trial was a randomised, double-blind, non-inferiority trial in 5,395 patients with acute VTE. Recurrent symptomatic VTE or VTE-related death was the primary efficacy endpoint whilst major bleeding was the primary safety outcome.1 Efficacy analyses were based on ITT population for whom the outcome status at 6 months was documented. Safety analyses were based on patients who had at least one dose of study drug.1
† The primary efficacy endpoint was the incidence of the adjudicated composite of recurrent symptomatic VTE or death related to VTE.1 Recurrent VTE included fatal or non-fatal PE and DVT.1 The primary safety endpoint was major bleeding.1
‡ This link is to a third-party site unaffiliated with the Pfizer / BMS Alliance. Please abide by the terms of use of the site.
AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy ARR = Absolute Risk Reduction CI = Confidence Interval DVT = Deep Vein Thrombosis ITT= Intention-to-Treat N = Total number of patients in the ELIQUIS group of the enoxaparin / warfarin group n = Number of patients with event PE = Pulmonary Embolism RR = Relative Risk RRR = Relative Risk Reduction VTE = Venous Thromboembolic Events
References
- Agnelli G et al. N Engl J Med 2013; 369: 799–808.